Singapore markets open in 1 hour 8 minutes

Straits Times Index
3,292.69
+10.64(+0.32%)
S&P 500
5,018.39
-17.30(-0.34%)
Dow
37,903.29
+87.37(+0.23%)
Nasdaq
15,605.48
-52.34(-0.33%)
Bitcoin USD
58,421.46
-2,424.39(-3.98%)
CMC Crypto 200
1,272.37
-66.69(-4.99%)

Hikma Pharmaceuticals PLC (HKMPF)

Other OTC - Other OTC Delayed price. Currency in USD

Add to watchlist

22.33

0.00

(0.00%)

At close: 09:49AM EDT

Trade prices are not sourced from all markets

All

Simply Wall St.
With 52% institutional ownership, Hikma Pharmaceuticals PLC (LON:HIK) is a favorite amongst the big guns
Key Insights Significantly high institutional ownership implies Hikma Pharmaceuticals' stock price is sensitive to...
Simply Wall St.
Optimism around Hikma Pharmaceuticals (LON:HIK) delivering new earnings growth may be shrinking as stock declines 3.3% this past week
In order to justify the effort of selecting individual stocks, it's worth striving to beat the returns from a market...
Reuters
Merck's Bridion faces generic threat from drugmaker Hikma
Merck has received a letter that Hikma Pharmaceuticals US unit has sought a pre-patent expiry approval from the US FDA to sell a generic version of its Bridion injection, the drugmaker said in filing on Monday. Merck said, on Feb. 5, it received the letter under the Hatch-Waxman Act, through which a company can seek FDA approval to market a copycat before the expiration of patents related to the brand-name drug. Merck said in the filing that it is currently considering its options.